Stock Learning

BAGSVAERD, DENMARK--(Marketwire - Feb 6, 2012) -

ROCKVILLE, MD--(Marketwire - Feb 6, 2012) - MarketResearch.com has announced the addition of the new report "Biomarkers Market (Discovery Technologies, Applications & Indications) - Global Trends, Opportunities & Forecasts (2011 - 2020)," to their collection of Biotechnology market reports. For more information, visit http://www.marketresearch.com/MarketsandMarkets-v3719/Biomarkers-Discovery-Technologies-Applications-Indications-6792106/

PALO ALTO, CA and STOCKHOLM, SWEDEN--(Marketwire - Feb 6, 2012) - Easy and cost-efficient two-factor authentication for single sign-on is now made available by a partnership between Yubico, the leading provider of simple, open online identity protection, and SSO Easy, provider of SAML server solutions.

STOCKHOLM, SWEDEN--(Marketwire - Feb 6, 2012) - Sobi and Biogen Idec have agreed to disclose further details on their agreement regarding development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs, which was restructured in February 2010. Under the new agreement, Biogen Idec assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain territories were changed.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2012) - Pyng Medical Corp. (TSX VENTURE:PYT) ("Pyng" or the "Company") today announced a loan (the "Loan") in the amount of US$220,000 from its largest shareholder Excelera Corporation ("Excelera"). The Loan carries interest at 11% per annum, is unsecured, and does not include an equity component. The total principal and interest is due on April 12, 2012.

HOUSTON, TX--(Marketwire - Feb 3, 2012) - Intergraph has scheduled CADWorx DraftPro webinars on February 15 at 10:00 a.m. and February 16, 2012 at 7:00 p.m. CT that will cover how to get started with pipe specifications, line numbers, and layouts using this new AutoCAD®-based intelligent 2D plant design and layout solution. The webinar will show how the built-in editor allows you to easily modify the supplied piping specifications to match your exact needs, saving time and providing accurate bills of material that require no manual modification. The webinar leader will be Sonia Delgadillo, senior CADWorx applications specialist at Intergraph CADWorx & Analysis Solutions group.

TORONTO, ONTARIO--(Marketwire - Feb. 3, 2012) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today announced that it has granted 100,000 incentive stock options to Mr. Simi Grossman, an independent member of the board of directors. The options are exercisable at $0.355 per share, based on markets prior day's close, for five years from the date of grant, are vested equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

BEDFORD, MA--(Marketwire - Feb 3, 2012) - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, announced plans to release its financial results for the fourth quarter and full year 2011 on February 9, 2012 after the close of the financial markets.

NEW YORK, NY--(Marketwire - Feb 3, 2012) - Corporate Profile's financial website www.CPreports.com announces Ray Dirks article on Medgenics, Inc. (NYSE Amex: MDGN).

TORONTO, ONTARIO--(Marketwire - Feb. 3, 2012) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") today announced that it will be conducting a non-brokered private placement equity financing under which it intends to issue up to 4,000,000 units at a price of $0.50 per unit for gross proceeds of $2,000,000. Each unit will be comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.75. The securities to be issued under the financing will be subject to a four month hold period.

BAGSVAERD, DENMARK--(Marketwire - Feb 3, 2012) -

BALTIMORE, MD--(Marketwire - Feb 3, 2012) - Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced the members of its Scientific Advisory Board, established to supplement its management team.

RICHMOND, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2012) - The BC Bioenergy Network ("BCBN"), a provincially-funded not for profit organization supporting the acceleration of bioenergy development in British Columbia, announced funding of $1.5 M to Fraser Richmond Soil and Fibre, a Harvest Power company. The project will establish an "EnergyGarden", an innovative municipal green (food and yard) waste to renewable energy demonstration in the Lower Mainland that will divert 27,000 tonnes of organic materials away from British Columbia landfills.

NEWTON, MA--(Marketwire - Feb 3, 2012) - Proventys, a leading developer of personalized decision support technologies for oncology and cardiology, announced that McKesson Corporation has acquired its CDS Oncology assets.

TAMPA, FL--(Marketwire - Feb 3, 2012) - Medical Device Development Group, specialists in the commercialization of medical devices, has announced a joint venture with Moffitt Cancer Center. The new organization, called Tampa Medical Innovations (TaMI), will commercialize medical device inventions envisioned by the Moffitt medical team.

OTTAWA, ONTARIO--(Marketwire - Feb. 3, 2012) - PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") today announced results from the most recent testing of its cancer drug Gap107B8 in mouse models of human ovarian cancer.

ROCHESTER, MI--(Marketwire - Feb 3, 2012) - OPTIMIZERx Corp (OTCBB: OPRX) announces key updates:

SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 3, 2012) - Threshold Pharmaceuticals, Inc (NASDAQ: THLD)

SAN DIEGO, CA--(Marketwire - Feb 2, 2012) - Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, will release fourth quarter and full year 2011 financial results after market close on Wednesday, February 29, 2012.

LONDON, ONTARIO--(Marketwire - Feb. 2, 2012) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that it has developed Phase 1 oral formulation candidates for COTI-2, a potentially first-in-class and best-in-class non-ATP competitive modulator/inhibitor of AKT/AKT2 that is being prepared for a Phase 1 clinical trial. The development of an oral formulation for use in humans attempts to maximize the amount of an orally administered drug that is absorbed and then circulates in the body.

NEW YORK, NY--(Marketwire - Feb 2, 2012) - TriMarkPublications.com cites in its newly published "Companion Diagnostics in Personalized Medicine and Cancer" report that the companion diagnostics market will explode as the personalized medicine market catapults to $42 billion by 2015. For more information, visit: http://www.trimarkpublications.com/products/Companion-Diagnostics-in-Personalized-Medicine-and-Cancer-Therapy.html.

CAMBRIDGE, MA--(Marketwire - Feb 2, 2012) - Molecular Insight Pharmaceuticals, Inc. (MIP) will present first human data on the molecular imaging of metastatic prostate cancer in bone and soft tissue with their new ^99mTc-radiolabeled compounds. The data will be highlighted at a scientific poster presentation on February 3, 2012 at the ASCO-2012 Genitourinary Cancers Symposium in San Francisco, CA. ^99mTc-MIP-1404 and ^99mTc-MIP-1405, internally developed at Molecular Insight, are technetium-99m-labeled small molecules that target prostate specific membrane antigen (PSMA), a protein expressed at high levels in primary and metastatic prostate cancer. The data demonstrated that ^99mTc-MIP-1404 and ^99mTc-MIP-1405 rapidly detected both bone and lymph node lesions in 6 metastatic prostate cancer patients and in some cases demonstrated a greater number of metastatic lesions in bone than bone scans, the standard of care for imaging skeletal metastases. Neither compound localized in the normal prostate gland, and both cleared from the blood rapidly, allowing rapid visualization of disease.

WOODBRIDGE, ONTARIO--(Marketwire - Feb. 2, 2012) - Pivotal Therapeutics Inc. (CNSX:PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health, today reports a Review and Update from the CEO.

ALEXANDRIA, VA--(Marketwire - Feb 2, 2012) - The American Diabetes Association announced today that Robert E. Ratner, MD, FACP, FACE has been named Chief Scientific and Medical Officer, effective May 7, 2012. Dr. Ratner is currently Professor of Medicine at Georgetown University Medical School and Senior Research Scientist at the MedStar Health Research Institute in metropolitan Washington, DC.

MONTRÉAL, QUÉBEC--(Marketwire - 2 fév. 2012) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui la nomination de Dr Henry J. Fuchs au conseil d'administration de la Société.

MONTREAL, QUEBEC--(Marketwire - Feb. 2, 2012) - MethylGene Inc. (TSX:MYG) is pleased to announce the appointment of Dr. Henry J. Fuchs to the Company's Board of Directors.

NEW YORK, NY--(Marketwire - Feb 2, 2012) - King & Spalding advised BioScrip, Inc. on the sale of certain assets of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens Co. for a total deal value of $225 million, which includes approximately $170 million in cash at closing and retention by BioScrip of associated accounts receivable and working capital liabilities of approximately $55 million, based on BioScrip's balance sheet values at December 31, 2011.

LOS ANGELES, CA--(Marketwire - Feb 2, 2012) - PHI Group, Inc. (OTCQB: PHIE) (PINKSHEETS: PHIE) announced today that Humex Medical Group, Inc. has signed an agreement with Tri Phuoc Co., Ltd, a Vietnamese company, to establish a stem cell center in Vietnam.

MELBOURNE, AUSTRALIA--(Marketwire - Feb 2, 2012) - Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today commented on three recent high profile scientific journal articles that the company believes provide support for Prana's therapeutic strategy for treating neurodegenerative disease.

MIAMI, FL--(Marketwire - Feb 2, 2012) - The Sclar Center for Empowered Dental Implant Learning in Miami offers a new and unique surgical training experience for specialists and general dentists. One of the components of this unique surgical training experience is the Sclar Center's Dental Implant Surgery Video Library. This online library is extensive and constantly growing. Participants in Sclar Center courses have online access to this library for one year after attending a Sclar Center course.

TORONTO, ONTARIO--(Marketwire - Feb. 2, 2012) - AbCelex Technologies Inc. is pleased to announce a strategic collaboration agreement with the Carton Group.

BERKELEY, CA--(Marketwire - Feb 2, 2012) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it met with the Food and Drug Administration (FDA) in a Pre-Biologics License Application (pre-BLA) meeting, and Dynavax and the FDA have agreed that the initial HEPLISAV BLA submission will be for an indication in healthy adults 18-70 years of age. This agreement represents a significant expansion of the previously anticipated population of healthy adults age 40 and over. In addition, it was confirmed that a supplemental BLA with an indication for patients with chronic kidney disease will be filed when the initial BLA is approved.

EDINA, MN--(Marketwire - Feb 2, 2012) - Excelsior Solutions, a leading national pharmacy consulting firm based in Minneapolis, announced today the hire of DeeDee Tillitt as the newest member of their national pharmacy consulting team.

LOS ANGELES, CA--(Marketwire - Feb 2, 2012) - In an exclusive interview with BioMedReports, Punit Dhillon, the President and CEO of OncoSec Medical Inc. (OTCBB: ONCS), explains some of the reasons why investors may be taking positions in the company after a slow but steady sell-off in the market.

PHOENIX, AZ--(Marketwire - Feb 2, 2012) - Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to announce the company CEO Dr. Hassan Salari providing an update on the company's progress on YouTube for the Company's lead therapeutic drug for erectile dysfunction X-Excite. The Company's second lead therapeutic drug KDM-1102 is a new sublingual formulation of Propanolol. The newest drug initiated into development is Gleevec®. Gleevec® is an important anti-cancer drug for the treatment of several blood related cancers in children and adults.

DEERFIELD, IL--(Marketwire - Feb 2, 2012) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, is scheduled to present at the 14^th Annual BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 1:30pm Eastern Time in New York, NY. Mr. Walbert will provide an overview of the Company and its corporate activities.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 2, 2012) - DelMar Pharma today announced that the United States FDA Office of Orphan Products Development has granted orphan drug designation for VAL-083 for the treatment of glioma, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

VAL-083 represents a 'first in class' small-molecule chemotherapeutic, which has been assessed in multiple NCI-sponsored clinical studies. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types, including GBM. DelMar Pharma has initiated a Phase I/II clinical trial of VAL-083 in patients with recurrent GBM, from which data is anticipated later this year.

LAVAL, QUÉBEC--(Marketwire - 2 fév. 2012) - Warnex Inc. (TSX:WNX) (« Warnex ») est heureuse d'annoncer qu'elle a conclu une entente avec Persistence Capital Partners LP (« PCP ») en vue de reporter la date d'échéance de l'une de ses débentures convertibles en cours détenue par PCP. À l'heure actuelle, PCP détient une débenture convertible de Warnex d'un capital de 1 230 969 $ venant à échéance le 31 janvier 2012 (la « débenture de janvier 2012 ») et une autre débenture convertible de Warnex d'un capital de 346 702 $ venant à échéance le 29 février 2012. Aux termes de l'entente conclue avec PCP, Warnex a versé 250 000 $ à PCP, à titre de paiement pour tous les intérêts et frais impayés actuellement dus à PCP et à titre de remboursement partiel du capital dû aux termes de la débenture de janvier 2012, en échange d'un report au 29 février 2012 de la date d'échéance du solde de la débenture de janvier 2012.

LAVAL, QUEBEC--(Marketwire - Feb. 2, 2012) - Warnex Inc. (TSX:WNX) ("Warnex") is pleased to announce that it has reached an agreement with Persistence Capital Partners LP ("PCP") to extend the maturity date of one of its outstanding convertible debentures held by PCP. PCP currently holds a convertible debenture of Warnex in the principal amount of $1,230,969 maturing on January 31, 2012 (the "January 2012 Debenture") and a further convertible debenture of Warnex in the principal amount of $346,702 maturing on February 29, 2012. Under the terms of the agreement reached with PCP, Warnex has paid $250,000 to PCP, in payment of all outstanding interest and fees currently owing to PCP and in partial repayment of the principal amount owing pursuant to the January 2012 Debenture, in exchange for an extension of the maturity date on the balance of the January 2012 Debenture to February 29, 2012.

BOISE, ID--(Marketwire - Feb 2, 2012) - MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the "Company") announced financial results today for its first quarter ended December 31, 2011.

PLANEGG, GERMANY and MUNICH, GERMANY--(Marketwire - Feb 2, 2012) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) (ISIN DE000A1A6XX4) announced that, upon the recommendation of the study Data Safety Monitoring Board (DSMB), the Company has stopped further enrollment and treatment in the Phase II/III OASIS trial with talactoferrin in severe sepsis. The DSMB made this recommendation based on a review of the available data from the trial, which indicated that 28-day mortality in the talactoferrin arm of the study was greater than in the placebo arm.

BAGSVAERD, DENMARK--(Marketwire - Feb 2, 2012) -

LEIDEN, NETHERLANDS--(Marketwire - Feb 2, 2012) - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today that a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S, a leading innovative pharmaceutical company. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed.

LEIDEN, THE NETHERLANDS--(Marketwire - Feb 2, 2012) - OctoPlus N.V. ("OctoPlus" or the "Company") (AMS: OCTO), announces today that a formulation development and manufacturing contract has been signed with Ferring Pharmaceuticals A/S, a leading innovative pharmaceutical company. The undisclosed contract value will make a material contribution to OctoPlus' 2012 revenues. Further details on the compound and activities are not disclosed.

BOTHELL, WA--(Marketwire - Feb 1, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's common stock will begin trading on the OTCQX tier of the OTC Markets commencing on Thursday, February 2, 2012. The Company has been advised that its shares will trade under its current symbol, "MRNA". Investors will be able to view real-time stock quotes for "MRNA" at http://www.otcmarkets.com/stock/MRNA/quote.

SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 1, 2012) - Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Chief Executive Officer, is scheduled to present at the following investor conferences in February 2012:

GHENT, BELGIUM--(Marketwire - Feb 1, 2012) -

LONDON--(Marketwire - Feb 1, 2012) - Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that there have been no material changes to its operations or its business affairs, and the Company is not aware of any undisclosed developments that would account for the recent unusual trading activity of its shares.

MARTINSRIED / MUNCHEN, GERMANY--(Marketwire - Feb 1, 2012) -

GLEN ALLEN, VA--(Marketwire - Feb 1, 2012) - Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), today announced a new partnership with GNC, the global health and wellness retailer that specializes in premium, value-added nutritional products. Beginning today, customers will be able to purchase AnatablocT through GNC's Internet storefront: http://www.gnc.com. AnatablocT assists the body's natural process for regulating inflammation using an alkaloid found in plants and vegetables, in combination with Vitamins A and D3, to help maintain healthy levels of inflammation. AnatablocT was introduced in August 2011 through a dedicated product website.

TORONTO, ONTARIO--(Marketwire - Feb. 1, 2012) - CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE:EKG) and TZ Medical, Inc. (TZM, Oregon) entered into a device integration and distribution agreement for the Mobile Cardiac Telemetry (MCT) electrocardiographic (ECG) and arrhythmia management market. Under this agreement, CardioComm Solutions will integrate TZM's new Aera CTT MCT monitor into their proprietary GEMST software. The GEMST MCT offering will be called GEMS Aera CT and it will be an extension of CardioComm Solution's popular GEMST Air (Global ECG Management System) solution.

WINNIPEG, MANITOBA--(Marketwire - Feb. 1, 2012) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that its PreVu^® Non-Invasive Skin Cholesterol Point of Care (POC) Test has been cleared for sale by Health Canada.

SAN DIEGO, CA--(Marketwire - Feb 1, 2012) - Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering are expected to be $144.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ardea. Ardea has granted the underwriters a 30-day option to purchase up to an aggregate of 1,275,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about February 6, 2012, subject to customary closing conditions. Ardea anticipates using the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to Phase 3 clinical trials of lesinurad, capital expenditures, working capital, and general and administrative expenses.

NEW YORK, NY--(Marketwire - Feb 1, 2012) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Shertech Pharmacy in Greenville, South Carolina. This agreement will provide Shertech with a Daxor BVA-100 Blood Volume Analyzer, an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis. Published studies using the BVA-100 have shown that blood volume measurement is important in treating heart failure, critical care patients in intensive care units, and in diagnosing the true status of complex anemias and syncope (fainting).

EDMONTON, ALBERTA--(Marketwire - Feb. 1, 2012) - Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product development, today announced that Syngenta AG has decided not to pursue its Right of First Refusal for Innovotech's seed treatment product, Agress®.

BAGSVAERD, DENMARK--(Marketwire - Feb 1, 2012) -

ROCKVILLE, MD--(Marketwire - Feb 1, 2012) - MarketResearch.com has announced the addition of the new report "Global HIV/AIDS Testing Market 2010-2014" to their collection of Diseases & Conditions market reports. For more information, visit http://www.marketresearch.com/Infiniti-Research-Limited-v2680/Global-HIV-AIDS-Testing-6773827/

BERLIN, GERMANY--(Marketwire - Feb 1, 2012) -

AURORA, ON--(Marketwire - Jan 31, 2012) - Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (das "Unternehmen" oder "Helix") gibt bekannt, dass die Jahreshauptversammlung ("JHV" oder die "Versammlung") heute wie geplant stattgefunden hat. Auf der JHV wurde der Jahresabschluss des Unternehmens vorgestellt und das Mandat der Abschlussprüfer KPMG LLP Chartered Accountants wurde erneuert.

AURORA, ON--(Marketwire - Jan 31, 2012) - Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (das "Unternehmen" oder "Helix") gibt bekannt, dass die Jahreshauptversammlung ("JHV" oder die "Versammlung") heute wie geplant stattgefunden hat. Auf der JHV wurde der Jahresabschluss des Unternehmens vorgestellt und das Mandat der Abschlussprüfer KPMG LLP Chartered Accountants wurde erneuert.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 31, 2012) -

SAN DIEGO, CA--(Marketwire - Jan 31, 2012) - Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BOULDER, CO--(Marketwire - Jan 31, 2012) - InDevR, Inc., a Boulder-based biotechnology company developing advanced life science instrumentation and assays for analysis of viruses and other microorganisms, announced today the appointment of Dr. Michael Artinger as Vice President of Commercial Operations and Mr. Craig Hoechstetter as Director of Sales and Customer Support.

SEATTLE, WA--(Marketwire - Jan 31, 2012) - Stratos Product Development LLC today announced its partnership with Mimic Technologies to advance the current design of the Mimic dV-Trainer, an independently validated, highly realistic simulation system for the da Vinci robot that improves patient safety and allows for surgical training, saving operating room time and reducing operational costs.

NEWBURYPORT, MA and NEW ORLEANS, LA--(Marketwire - Jan 31, 2012) - Informex, Booth 425 -- PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has significantly increased its bench strength in quality control and research and development with the hiring of several experts in recent months.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 31, 2012) - Functional Technologies Corp. (TSX VENTURE:FEB) (the "Company") announced Mr. Christopher Morris has been appointed Acting Chief Executive Officer (CEO). This enables Mr. Howard Louie, who remains as Executive Chairman and assumes the responsibilities of Chief Business Development Officer (CBDO), to focus exclusively on the Company's activities in cultivating and executing on strategic relationships associated with its lead technologies, as well as his ongoing capital market efforts.

LIONVILLE, PA--(Marketwire - Jan 31, 2012) - West Pharmaceutical Services, Inc. (NYSE: WST) today announced that management will attend the UBS 22nd Annual Global Healthcare Services Conference in New York, NY. Management will present an overview of West's business and outlook on Tuesday, February 7, 2012 at 3:00 PM ET.

ROCKVILLE, MD--(Marketwire - Jan 31, 2012) - MarketResearch.com has announced the addition of the new report "Global Diabetes Devices Market 2010-2014," to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/Infiniti-Research-Limited-v2680/Global-Diabetes-Devices-6773755/

OREM, UT--(Marketwire - Jan 31, 2012) - Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries announced a letter to shareholders outlining the 2012 strategic plan.

OKLAHOMA CITY, OK--(Marketwire - Jan 31, 2012) - Cytovance Biologics® announced today that it is has added a 1,000L bioreactor to its current mammalian facility with appropriate downstream processing facilities. Cytovance Biologics® currently specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from batch, fed-batch and perfusion processes and microbial production up to the 100L scale.

MELBOURNE, AUSTRALIA--(Marketwire - Jan 31, 2012) - Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced it has filed its Quarterly Activities Report and Appendix 4C for period ending December 31, 2011 in accordance with the ASX.

ROCKVILLE, MD--(Marketwire - Jan 31, 2012) - MarketResearch.com has announced the addition of the new report "Global Dental Implants Market 2010-2014," to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/Infiniti-Research-Limited-v2680/Global-Dental-Implants-6773797/

STOCKHOLM, SWEDEN--(Marketwire - Jan 31, 2012) -

AURORA, ON--(Marketwire - Jan 30, 2012) - Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (the "Company" or "Helix") announces that its Annual General Meeting ("AGM" or the "Meeting"), was held today as scheduled. The financial statements of the Company were placed before the AGM and the auditors, KPMG LLP Chartered Accountants, were reappointed.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE:PGA) announced today that the Company has signed an amendment to its license agreement with Demegen, Inc., to expand its exclusive worldwide rights and license to PAC-113 for additional indications, including vaginal, dermatological and ophthalmic applications. There was no payment associated with the amendment license agreement. All other terms of the license agreement remained unchanged. Pacgen has right to sublicense all these additional indications as well as oral indications covered in its original license.

ANN ARBOR, MI--(Marketwire - Jan 30, 2012) - MichBio announced that it has formed a Medical Devices, Technology & Manufacturing Committee to enhance its representation and resource capacity for this important biosciences industry sector.

ROCKVILLE, MD--(Marketwire - Jan 30, 2012) - The Tech Council of Maryland (TCM), Maryland's largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today announced that Art Jacoby, a TCM board member and managing partner at Maryland Cyber Investment Partners, will serve as the association's interim CEO.

FARMINGTON, CT--(Marketwire - Jan 30, 2012) - BroadcastMed, Inc. is proud to present the health community with an online resource for quality, video content. The recently launched NEP Video Center contains videos on specialties ranging from cancer to pediatrics to orthopedics. This Wednesday, a new program launches on the site highlighting the otolaryngology department at NewYork-Presbyterian. Viewers will learn from top specialists on treating a wide-range of ear, nose, and throat conditions.

FARMINGTON, CT--(Marketwire - Jan 30, 2012) - There are a variety of reasons why thyroid surgery is performed including thyroid cancer, problems related to enlarged thyroid, and treatment for hyperthyroidism. This Wednesday, online views will get a firsthand look at how surgeons perform a thyroidectomy during a live webcast program from Homestead Hospital in Homestead, Florida. General surgeon, George Tershakovec, MD, will perform the procedure and viewers are encouraged to email questions to the operating room.

GLEN ALLEN, VA--(Marketwire - Jan 30, 2012) - Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), has completed the first successful human clinical trial showing that AnatablocT, the dietary supplement developed by Rock Creek to provide anti-inflammatory support, lowers C-reactive protein (CRP) levels in subjects' blood. CRP is a molecule produced by the liver in response to an inflammatory signal, and is a marker for inflammation. The company is today reporting initial results from Phase 2 of the RCP-006 study titled "A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Efficacy of AnatablocT, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers, Followed by an Open-Label Extension Period." The trial consisted of 105 subjects, all of whom were smokers and 79% of whom were overweight or obese. Research increasingly links inflammation to a variety of diseases such as Alzheimer's disease, thyroiditis and diabetes, as well as cardiovascular disease.

BUENA PARK, CA--(Marketwire - Jan 30, 2012) - SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceuticals, nutraceutical and dermatology company that manufactures and markets generic drugs covering all major treatment categories, today announced its launch of additional dermatology products into Indian market.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB:REPCF) is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman - both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - In March of 1993, Penny Flynn and Jeff Date received devastating news: their nine-month-old daughter Taylor had been diagnosed with medulloblastoma, a cancerous brain tumour. Cancer is the leading cause of non-accidental deaths in children, and medulloblastoma is the most common form of childhood cancer. The few children who do survive the aggressive and debilitating treatments must then often cope with a host of side-effects, such as learning challenges and physical disabilities. In essence, saving the child's life is an important initial victory, but also the start of life-long challenges for the child, their family and the health care system.

SAN DIEGO, CA--(Marketwire - Jan 30, 2012) - SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE), a San Diego based medical device company, today announced it has named Hughes Wielemans as Director of Business Development, Europe, effective February 1.

IRVINE, CA--(Marketwire - Jan 30, 2012) - The Board of Directors of ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today reiterated its commitment to maximizing shareholder value and said it will continue its previously announced review of all strategic options available to the Company. The Board issued its statement in response to a press release from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announcing that Valeant had withdrawn its unsolicited proposal to acquire ISTA.

SEATTLE, WA--(Marketwire - Jan 30, 2012) - Plandaí Biotechnology, Inc. (OTCBB: PLPL) Chief Executive Officer, Roger Duffield, today announced that Dr. Tom Matula has accepted the position of Chairman of the Scientific Board for Plandaí Biotechnology, Inc., effective immediately.

WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).

SAVI-PCI (pronounced savvy) will be a randomized, open-label study enrolling approximately 600 patients undergoing percutaneous coronary intervention (PCI) at sites across the United States. The study is designed to evaluate whether patients receiving the investigational, High-Dose Bolus (HDB) regimen of AGGRASTAT (25 mcg/kg bolus over 3 minutes) followed by an infusion of 0.15 mcg/kg/min for a shortened duration of 2 hours will have outcomes that are similar, or "non-inferior," to patients receiving an 18 hour infusion of Integrilin® (eptifibatide) (Merck & Co., Inc.) at its FDA approved dosing regimen. The primary objective of SAVI-PCI is to demonstrate AGGRASTAT is non-inferior to Integrilin with respect to the composite endpoint of death, PCI-related myocardial infarction, urgent target vessel revascularization, or major bleeding within 48 hours following PCI or hospital discharge. The secondary objectives of this study include the assessment of safety as measured by the incidence of major bleeding. The first patient is anticipated to be enrolled in spring 2012. The Principal Investigator for the study is Steven V. Manoukian, MD, Director of Cardiovascular Research at the Sarah Cannon Research Institute (SCRI).

SAN DIEGO, CA--(Marketwire - Jan 30, 2012) - Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) to treat a form of coronary heart disease, chronic myocardial ischemia (CMI). The IDE application was originally submitted to the FDA in December 2011.

IRVINE, CA--(Marketwire - Jan 30, 2012) - ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced it has successfully enrolled more than 600 patients in the Company's Phase 2 clinical study of its BEPOSONET nasal spray combining bepotastine besilate with a steroid for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study is evaluating the safety and efficacy of the combination nasal spray, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.

TORONTO, ONTARIO--(Marketwire - Jan. 30, 2012) - BioExx Specialty Proteins Ltd. ("BioExx" or the "Company") (TSX:BXI), the first company to commercialize a new and complete food-grade protein from a major global crop since the introduction of soy protein isolate some 60 years ago, is pleased to provide the following update on its business activities:

Plant Update

ROCKVILLE, MD--(Marketwire - Jan 30, 2012) - MarketResearch.com has announced the addition of the new report "Clinical Trial Management Systems (CTMS) Market Global Trends, Opportunities, Challenges & Forecasts (2011 - 2016)," to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/MarketsandMarkets-v3719/Clinical-Trial-Management-Systems-CTMS-6774250/